{"id":"NCT02319031","sponsor":"Bristol-Myers Squibb","briefTitle":"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","officialTitle":"Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02","primaryCompletion":"2015-10","completion":"2015-12","firstPosted":"2014-12-18","resultsPosted":"2017-01-27","lastUpdate":"2017-01-27"},"enrollment":53,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Daclatasvir","otherNames":[]},{"type":"DRUG","name":"Sofosbuvir","otherNames":[]},{"type":"DRUG","name":"Ribavirin","otherNames":[]}],"arms":[{"label":"Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)","type":"ACTIVE_COMPARATOR"},{"label":"Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced fibrosis or compensated cirrhosis. Patients in this study may have already been treated prior for HCV or may have never received treatment for their HCV.","primaryOutcome":{"measure":"Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)","timeFrame":"Follow-up Week 12","effectByArm":[{"arm":"Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)","deltaMin":87.5,"sd":null},{"arm":"Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)","deltaMin":92.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":10,"countries":["Australia","France"]},"refs":{"pmids":[],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":24},"commonTop":["Insomnia","Fatigue","Headache","Irritability","Asthenia"]}}